{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=niraparib&page=2", "query": { "intervention": "niraparib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=niraparib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-10T20:12:56.900Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01847274", "title": "A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Platinum Sensitive Ovarian Cancer" ], "interventions": [ { "name": "Active comparator: Niraparib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 596, "start_date": "2013-06-21", "completion_date": "2021-12-26", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01847274" }, { "nct_id": "NCT03431350", "title": "A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Niraparib 200 mg", "type": "DRUG" }, { "name": "Cetrelimab 240 mg", "type": "DRUG" }, { "name": "Cetrelimab 480 mg", "type": "DRUG" }, { "name": "Abiraterone acetate 1000 mg", "type": "DRUG" }, { "name": "Prednisone 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2018-03-02", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 19, "location_summary": "Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Towson", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03431350" }, { "nct_id": "NCT06433219", "title": "Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Tuvusertib (M1774)", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Lartesertib (M4076)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2024-10-30", "completion_date": "2026-06-14", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06433219" }, { "nct_id": "NCT02657889", "title": "Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms", "Triple Negative Breast Cancer", "Ovarian Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Stage IV Breast Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "niraparib", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2016-04-15", "completion_date": "2021-09-17", "has_results": true, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02657889" }, { "nct_id": "NCT04502602", "title": "Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer" ], "interventions": [ { "name": "Neratinib 160 mg", "type": "DRUG" }, { "name": "Neratinib 200 mg", "type": "DRUG" }, { "name": "Neratinib 240 mg", "type": "DRUG" }, { "name": "Niraparib 100 mg", "type": "DRUG" }, { "name": "Niraparib 200 mg", "type": "DRUG" }, { "name": "Niraparib 300 mg", "type": "DRUG" }, { "name": "Niraparib at RP2D", "type": "DRUG" }, { "name": "Neratinib at RP2D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-08-24", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04502602" }, { "nct_id": "NCT03981796", "title": "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Placebo matching dostarlimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Placebo matching Niraparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 785, "start_date": "2019-07-18", "completion_date": "2026-11-26", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981796" }, { "nct_id": "NCT06747845", "title": "Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2025-05-07", "completion_date": "2029-01-30", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06747845" }, { "nct_id": "NCT07477756", "title": "A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1247, "start_date": "2024-09-04", "completion_date": "2025-03-14", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477756" }, { "nct_id": "NCT03945721", "title": "A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Residual Disease" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-07-11", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945721" }, { "nct_id": "NCT04475939", "title": "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer, Non-Small Cell" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 666, "start_date": "2020-10-26", "completion_date": "2026-03-23", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-10T20:12:56.900Z", "location_count": 21, "location_summary": "Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04475939" } ] }